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CHAPTER	ONE	
REVIEW	OF	THE	LITERATURE	
Human	Immunodeficiency	Virus	I	
Human	Immunodeficiency	Virus	type	1	(HIV-1)	was	first	discovered	to	cause	Acquired	
Immune	Deficiency	Syndrome	(AIDS)	in	1983	and	since	then,	continues	to	be	a	serious	health	
issue	in	many	parts	of	the	world,	particularly	Sub-Saharan	Africa	and	the	Americas	(26).	
Historically	about	35	million	people	have	died	resulting	in	an	HIV	related	illness	and	70	million	
people	have	been	infected	with	the	virus.	Today,	an	estimated	36.7	million	people	are	living	
with	HIV,	with	approximately	2.1	million	new	cases	annually	(27).		
HIV-1	is	known	to	infect	CD4+	T	cells,	macrophages	and	microglial	cells	of	the	immune	
system.	Both	CD4+	T	cells	and	macrophages	express	the	CD4	molecule	on	their	cell	surface,	as	
well	as	the	chemokine	receptor	CCR5,	both	of	which	are	utilized	by	HIV-1	for	cellular	entry.	Viral	
binding	and	entry	is	the	first	step	in	the	viral	lifecycle	(4,	5).	The	sequential	binding	of	viral	
protein	gp120	to	both	CD4	and	CCR5	initiates	fusion	of	the	virus	and	plasma	membranes,	as	the	
virus	is	brought	in	close	proximity	to	the	target	cell.	Following	fusion,	the	viral	core	trafficks	
through	the	cytoplasm,	during	which	time	the	virus	begins	reverse	transcribing	its	RNA	genome	
into	the	double	stranded	DNA	form	that	it	ultimately	integrated	into	the	host	cell	genome	via	
the	viral	protein	Integrase	(4,	5).	Upon	integration,	transcription	results	in	the	early	synthesis	of	
regulatory	HIV-1	proteins,	of	which	assist	in	generating	longer	RNA	transcripts.	Subsequently,	
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these	newly	structured	proteins	are	assembled	at	the	cell	surface	and	released	as	a	new,	
mature	virion	following	its	budding	from	the	host	cell	plasma	membrane	(4,	5).		
The	pathogenesis	of	HIV-1	infection	is	a	consequence	of	both	the	infecting	virus,	as	well	
as	the	host’s	immune	response	to	the	virus.	Viral	transmission	requires	direct	exposure	and	is	
highly	dependent	on	the	virus	isolate,	its	concentration	and	host	susceptibility.	CD4+	T	cells	are	
the	first	to	become	infected,	spreading	the	virus	into	the	regional	lymph	nodes	and	
subsequently	into	the	bloodstream	(4,	5).	Viral	replication	is	at	its	height	during	this	acute	
phase	of	the	primary	infection;	virus	particles	can	be	found	in	dendritic	cells,	CD4+	T	cells	and	
macrophages.	Infected	cells	typically	succumb	to	the	infection,	undergoing	cell	death	or	
establishing	a	form	of	latent	infection.	During	this	stage	of	infection,	the	number	of	CD4+	T	cells	
dramatically	declines	as	viral	titers	rapidly	increase,	yet	this	response	is	short	lived	as	the	host	
generates	humoral	and	cellular	immune	responses	(4,	5).	Upon	Antibody-Dependent	Cellular	
Cytotoxicity,	mediated	by	Natural	Killer	T	cells	and	HIV-specific	T	cells	and	antibodies,	HIV-1	
RNA	levels	decline	and	CD4+	T	cells	raise	again,	although	never	fully	recovering	from	the	
persistent	infection.	The	HIV-1	pathogenic	effects	persist,	albeit	asymptomatic,	resulting	in	the	
progressive	loss	of	CD4+	T	cells	and	viral	spread	within	the	lymphoid	environments.	In	the	
absence	of	treatment,	patients	develop	AIDS	and	typically	succumb	to	opportunistic	infections	
due	to	their	weakened	immune	system	(Figure	1).		
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Figure	1.	Treatment-Naïve	HIV-1	Time	Course.	A	schematic	of	treatment-naive	HIV-1	infection	time	
course	in	which	viral	RNA	copies	are	represented	in	red	and	CD4+	T	cell	count	in	blue.	HIV-1	RNA	copies	
are	steadily	increasing,	while	CD4+	T	cells	are	rapidly	declining	during	the	stage	of	primary	infection.	As	
time	progresses	latent	reservoirs	are	established	resulting	in	clinical	latency.	With	a	lack	of	treatment,	
opportunistic	infections	arise	and	HIV-1	disease	will	progress	into	AIDS.		
	
	
	
	
	
	
	
	
	
	
	
	
	
In	the	past	20	years,	HIV-1	infection	has	transitioned	from	a	life-limiting	disease	often	
met	with	fatal	opportunistic	infections	to	a	manageable	chronic	infection	with	a	near-normal	
life	span	and	few	opportunistic	infections.	This	transition	has	been	made	possible	through	four	
major	advancements	both	in	the	patient	care,	as	well	as	scientific	research	advancements	
including:	gaining	a	better	understanding	of		HIV-1	replication	and	the	subsequent	relationship	
of	immunological	and	clinical	progression,	the	development	and	utilization	of	combination	
antiretroviral	therapy	(CART),	the	ability	to	optimize	patient	treatment	via	reliable	
measurements	of	CD4+	helper	T	cells,	plasma	HIV-1	RNA	levels	and	antiretroviral	resistance	
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profiles,	and	lastly	the	shift	of	treatment	with	beginning	CART	upon	HIV-1	infection	and	patient	
commitment	regardless	of	CD4+	T	cell	count	(26,	27).		
CART	works	to	limit	HIV-1	viral	replication	through	inhibition	of	multiple	stages	in	the	
HIV-1	life	cycle	(Figure	2).	Specifically,	nucleoside	and	nucleotide	reverse	transcriptase	
inhibitors	suppress	viral	replication,	integrase	inhibitors	work	by	blocking	the	incorporation	of	
the	viral	genome	into	host	DNA,	and	protease	inhibitors	prevent	the	proteolytic	cleavage	of	
protein	precursors	required	for	the	production	of	viral	particles	(4,	5).	Combination	therapies	
are	advantageous	in	that	they	greatly	decrease	the	risk	of	the	evolution	of	drug-resistant	
strains.	Unfortunately,	in	2016	it	was	estimated	that	only	17	million,	or	about	46%	of	the	36.7	
million	individuals	living	with	HIV-1,	were	actually	receiving	CART	(26,	27).		
	 While	CART	has	significantly	reduced	the	mortality	associated	with	HIV-1,	these	
therapies	are	unable	to	completely	eradicate	the	infection.	This	is	because	HIV-1	is	capable	of	
establishing	latency,	primarily	within	infected	CD4+	T	cells,	creating	what	are	known	as	latent	
reservoirs	throughout	the	body	(4,	5).	If	CART	is	stopped	or	temporarily	interrupted,	the	virus	
can	rapidly	rebound,	viral	replication	will	resume	and	lead	to	AIDS	if	treatment	is	not	resumed.	
Furthermore,	patients	on	CART	are	at	an	increased	risk	for	a	number	of	inflammatory	
complications,	including,	cardiovascular	disease,	renal	complications	and	HIV-Associated	
Neurocognitive	Disorders.		
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Figure	2.	HIV-1	Time	Course	Following	CART	Treatment.	A	schematic	of	HIV-1	disease	progression	with	
introduction	to	CART,	in	which	CD4+	T	cell	count	and	HIV-1	RNA	levels	are	depicted	against	treatment	timeline.	
CD4+	T	cells	are	rapidly	declining,	while	HIV-1	RNA	copies	are	steadily	increasing	prior	to	CART	introduction.	
Once	treatment	begins,	CD4+	T	cell	count	recovers,	while	measurable	HIV-1	RNA	levels	are	at	a	steady	decline.																																																																																																													
(Adapted	from	Rohrbach,	J.,	et	al.)	
 
	
	
	
	
	
	
	
	
	
	
	
	
HIV-Associated	Neurocognitive	Disorders	
	 Prior	to	treatment	options	which	were	not	introduced	into	the	mid-1990s,	HIV-
associated	dementia	(HAD)	was	relatively	common	affecting	at	least	20	percent	of	HIV-1	
infected	individuals.	HAD	is	the	most	severe	form	of	cognitive	impairment	associated	with	
infection	and	is	described	as,	“marked	cognitive	impairment	involving	at	least	two	cognitive	
domains	that	substantially	interferes	with	daily	functioning”	(23,	p.	234).	Almost	always	fatal,	
HAD	has	substantially	declined	since	the	use	of	CART	and	is	now	rare	in	the	developed	world.	
Still,	CART	compliant	HIV-1	positive	individuals	experience	a	spectrum	of	neurocognitive,	
behavioral	and	motor	dysfunctions,	decreasing	their	quality	of	life.	Collectively,	these	infection-
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associated	inflammatory	complications	are	known	as	HAND,	or	HIV-Associated	Neurocognitive	
Disorders,	and	its	neuropathogensis	remains	an	important	unresolved	issue	(1-3,	23).	
Historically,	encephalitis	and	neuronal	loss	were	thought	to	play	a	central	role	in	the	
pathogenesis	of	HAD	yet	these	pathologies	are	no	longer	typical,	therefore	no	longer	sufficient	
in	providing	an	explanation	of	the	neurological	dysfunction	in	the	CART	era.	The	continuation	of	
HAND	pathology,	despite	viral	treatment	plans,	suggest	an	underlying	pathophysiology	more	
likely	associated	with	the	functional	alterations	in	neurons	(7,	8).		
	 Neurological	involvement	and	changes	in	brain	structure	occurs	very	rapidly	after	
infection;	within	the	first	few	months	following	infection,	reductions	in	brain	volume,	decreases	
in	white	matter	and	increased	permeability	of	the	blood-brain	barrier	have	been	observed.	
Moreover,	an	increase	in	circulating	levels	of	inflammatory	cytokines,	acute	metabolic	
disturbances,	and	immune	activation	accompany	measurable	deficits	in	cognitive	and	
psychomotor	functions	(7,	8).	Unfortunately,	many	of	these	modifications	do	not	improve	and	
even	have	been	shown	to	worsen	over	time	following	the	initiation	of	CART,	although	systemic	
viral	suppression	has	been	achieved.		
	 	The	relative	inaccessibility	of	the	affected	brain	tissue	hinders	our	understanding	of	the	
pathogenic	mechanisms	underlying	HAND;	although,	contemporary	pathological	studies	of	
CART-treated	individuals	report	unfavorable	changes	in	white	matter	integrity,	with	clear	signs	
of	inflammation	and	neuronal	damage	(7,	8).	This	neuronal	dysfunction	may	be	due	to	a	
number	of	infected	cells	such	as	perivascular	macrophages,	astrocytes	and	microglia	via	a	range	
of	mechanisms	poorly	defined.	CART-compliant	patients	have	limited	brain-localized	HIV-1	
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replication	suggesting	that	HAND	is	not	the	sole	consequence	of	viral	replication	but	may	be	the	
result	of	viral	protein	expression	in	infected	glial	cells	which	are	able	to	induce	toxicity	and	
death	of	nearby	neuronal	cells	(23,	31).	Early	and	progressive	disturbances	of	bioenergetics,	as	
well	as,	evidence	for	abnormal	glutamate	homeostasis	have	been	implicated	in	the	cause	of	
neuronal	injury	and	death	(23).	A	model	proposed	by	Saylor	et	al.,	outline	the	possible	
neuropathogenic	mechanisms	that	contribute	to	HAND:		
HIV-infected	macrophages	and	microglial	cells	release	neurotoxic	viral	proteins	that	
trigger	astrocyte	activations,	which	results	in	increased	glutamate	release	and	reduced	
glutamate	uptake.	Elevated	extracellular	glutamate	levels	cause	neuronal	bioenergetic	
disturbances	that	lead	to	aberrant	synaptodendritic	pruning	and	neuronal	injury.	Moreover,	
systemic	inflammation	and	microbial	translocation	products	lead	to	microglial	activation	and	
increased	production	of	chemokines	and	cytokines	that	contribute	to	neuronal	injury	(23,	p.	
240).		
	
Extracellular	Vesicles	and	HIV-Associated	Neurocognitive	Disorders	
To	date,	the	mechanism	by	which	HIV-1	infected	monocytes	induce	neurotoxicity	to	
neighboring	cells	is	unknown,	although	a	number	of	studies	suggest	extracellular	vesicles	may	
be	responsible	(12-14,	16,	17,	34).	Extracellular	vesicles	packaged	with	pathological	proteins,	
such	as	amyloid	beta	and	alpha-synuclein,	have	been	shown	to	induce	pathology	in	neighboring	
neuronal	cells	of	neurodegenerative	diseases	including	Alzheimer’s	and	Parkinson’s,	
respectively	(6,	15,	18,	21).	Furthermore,	there	is	emerging	evidence	that	HIV-1	infected	cells	
induce	the	release	of	extracellular	vesicles	containing	viral	RNA,	microRNA	and	viral	proteins	
resulting	in	the	altered	gene	expression	and	other	pathological	consequences	in	neighboring	
cells	exposed	to	these	extracellular	vesicles.	This	extracellular	vesicle-mediated	neurotoxicity	
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may	be	the	source	of	neuropathology	in	HAND	(12-14,	16,	17,	34).	If	so,	neurotoxic	extracellular	
vesicles	may	contribute	to	HAND	symptoms	in	CART	treated	patients	who	continue	to	present	a	
significant	reduction	or	even	minimal	levels	of	ongoing	viral	replication.	As	such,	it	is	possible	
that	the	role	of	extracellular	vesicles	in	HAND	is	similar	to	their	role	in	other,	above	mentioned,	
neurodegenerative	diseases.	There	are	a	number	of	HIV-1	RNA	and	proteins	that	have	been	
implicated	in	the	neuropathological	spread	HAND,	yet	this	study	will	focus	on	three	HIV-1	
proteins,	Nef,	Tat	and	Vpr,	which	have	been	implicated	in	the	progression	of	HAND,	and	are	
known	to	be	associated	with	extracellular	vesicles.		
Nef,	or	Negative	Regulatory	Factor,	is	a	27-34	kDa	myristoylated	protein	involved	in	
multiple	functions	during	the	replication	cycle	of	HIV	(22).	Nef	is	known	to	increase	viral	
infectivity	through	various	actions	such	as	activation	of	T	cell	signaling	pathways,	promoting	
particle	release,	causing	CD4	receptor	down	modulation	and	anti	apoptotic	signaling	(9,	10).	
This	HIV-1	protein	consists	of	a	N-terminal	myristoyl	(14-carbon)	lipid	attached	to	the	second	
glycine	reside	and	many	positive	charges	in	the	first	22	amino	acids,	constituting	Nef	as	a	
membrane-associated	protein	(22).	
Nef	expression	occurs	early	during	HIV-1	infection	of	CD4+	T	cells,	macrophages	and	
astrocytes,	and	has	been	known	to	be	released	form	these	cells	as	a	cargo	protein	in	
extracellular	vesicles	(9,10).	Neurotoxic	effects	of	Nef	including	neurological	degeneration,	
cytokine	production	and	negative	alterations	in	cellular	pathways	were	discovered	using	
recombinant	Nef	on	human	glial	cells	and	neurons.	Moreover,	animal	studies	in	rats	exhibited	
HIV-1	Nef-induced	neurocognitive	impairments	(89).	Lastly,	a	recent	study	performed	by	
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Saribas	et	al.,	concluded	that	HIV-1	Nef	is	released	in	extracellular	vesicles	derived	from	primary	
human	astrocytes	and	that	these	vesicles	are	taken	up	by	primary	human	neurons,	causing	
axonal	and	neurite	degeneration	(88).		
The	HIV-1	protein	Tat,	or	Trans-Activator	of	Transcription,	consists	of	86-101	amino	
acids	depending	on	the	subtype	and	has	been	suggested	as	a	causative	agent	in	HAND	due	to	
its	neuroexcitatory	and	neurotoxic	abilities	(11).	Being	one	of	the	three	early	encoded	proteins,	
Tat	is	required	for	viral	replication	through	its	interaction	with	its	response	element	of	the	HIV-
1	long	terminal	repeat,	allowing	for	the	phosphorylation	of	RNA	polymerase	II	thus	resulting	in	
the	synthesis	of	HIV-RNA	transcripts	(11).	Furthermore,	Tat	has	been	shown	to	be	released	by	
HIV-1	infected	CD4+	T	cells	and	taken	up	by	uninfected	“bystander”	T	cells	directly	resulting	in	
cellular	apoptosis.	It	has	been	hypothesized	that	due	to	its	lack	of	signal	sequence,	Tat	may	
follow	an	unconventional	secretory	pathway	allowing	for	its	release	(90).		
Tat	is	transported	across	the	blood	brain	barrier	by	systemic	circulation,	secreted	by	
infected	macrophages	and	microglia,	and	has	been	detected	in	brain	of	patients	with	HAND.	Tat	
has	also	been	associated	with	extracellular	vesicles	released	from	HIV-1	infected	CD4+	T	cells	
and	when	applied	to	neurons,	results	such	as	shorter	or	no	visible	neurites	and	significant	
neuronal	cell	death	became	apparent	(90).	These	results	suggest	that	extracellular	vesicle	
associated	Tat	is	biologically	active.	Furthermore,	a	recent	study	described	by	Hui	et	al.,	
concluded	that	Tat	was	found	to	induce	significant	neuronal	cell	death	from	48	hours	of	
treatment,	with	a	maximum	death	rate	of	50%	after	96	hours.	After	incubation	of	Tat	with	
neurons,	Tat	was	found	to	be	compartmentalized	in	endolysosomes;	moreover,	significant	size	
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increases	and	aggregation	of	endolysosomes	was	observed	(90).	Interestingly,	autophagic	
dysfunctions	have	been	implicated	in	the	pathogenesis	of	HAND	and	Tat	treated	neurons	have	
been	shown	to	have	decreased	levels	of	pro-autophagic	proteins,	and	increased	levels	of	
autophagic	inhibitory	proteins	(90).		
	 The	Viral	Protein	R,	or	Vpr,	is	a	14	kDa	protein	which	induces	G2	cycle	arrest	and	causes	
apoptosis	in	proliferating	cells	(30,	32).	In	the	context	of	macrophages,	Vpr	has	been	known	to	
interact	with	molecular	pathways	resulting	in	the	sequestration	of	proinflammatory	
transcriptional	activators	causing	immunosuppression,	thus	allowing	for	the	establishment	and	
maintenance	of	a	systemic	infection.	Vpr	has	been	identified	to	modify	host	cell	energy	
metabolism,	proteasome	function,	and	oxidative	status,	yet	while	this	protein	has	been	
extensively	studied	in	the	context	of	HIV-1	infection,	the	precise	mechanism	of	action	remains	
enigmatic	(91).		
Recently	James	et	al.	described	VPR	as	having	a,	“unique	role	in	neuropathogensis”	and	
that	through	extracellular	vesicle	based	intercellular	communication	VPR	has	deleterious	
effects	(30,	p.	409).	Furthermore,	VPR	was	found	among	the	extracellular	vesicle	population	
released	from	HIV-1	infected	lymphocytic	cells	in	a	study	published	by	Li	et	al.	in	2013	(31).		
Extracellular	Vesicle	Formation	
Originally	thought	to	be	the	cell’s	disposal	mechanism	of	discarding	unwanted	materials,	
extracellular	vesicles	have,	in	the	last	twenty	years,	become	a	topic	of	interest	as	they	have	
been	implicated	in	various	cellular	processes	such	as	cell	proliferation,	differentiation,	death	
and	cellular	immune	responses	(33,	34).	A	look	into	the	cargo	of	extracellular	vesicles	allows	for	
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the	presumption	that	these	proteins,	nucleic	acids,	miRNAs,	and	other	cargoes	are	specifically	
and	intentionally	packaged	into	extracellular	vesicles,	rather	than	representing	“trash”	
packaged	for	the	removal	from	the	cell.	Extracellular	vesicles,	ranging	in	size	from	30	to	1000	
nm,	are	often	categorized	based	on	size	into	more	precise	populations	such	as	exosomes,	
microvesicles,	ectosomes	or	apoptotic	bodies;	for	the	purpose	of	study	I	will	continue	to	utilize	
the	inclusive	term	“extracellular	vesicles”.	
Extracellular	vesicles	may	be	the	result	of	secretion	directly	from	the	plasma	membrane,	
released	following	the	endocytic	pathway,	or	can	be	the	product	of	autophagic	unconventional	
secretion	(19,	20,	56-58).	The	biogenesis	of	extracellular	vesicles	released	directly	from	the	
plasma	membrane	are	the	result	of	outward	budding	and	fission	of	the	plasma	membrane.	A	
number	of	events	will	allow	for	their	release,	such	as	the	redistribution	of	phospholipids,	
contraction	of	actin-myosin	machinery	or	a	calcium	influx	and	hypoxia,	to	name	a	few	(24,	25,	
28).	A	more	detailed	cascade	of	events	allowing	for	extracellular	release	directly	from	the	
plasma	membrane	includes	the	activation	of	phospholipase	D	via	ADP-ribosylation	factor	6	this,	
in	turn,	allows	for	the	recruitment	of	extracellular	signal-regulated	kinase	(ERK).	ERK	
phosphorylates,	thereby	activating	the	myosin	light	chain	kinase,	triggering	the	release	of	
extracellular	vesicles	(24,	25,	28).		
Endosomes	are	clatherin-coated	vesicles	located	within	cells	and	can	be	derived	either	
from	the	exocytic	or	endocytic	pathways	(25,	49,	54,	85).	Endosomes	can	be	further	classified	
into	early,	late,	or	recycling	endosomes.	Early	endosomes	are	the	first	to	receive	incoming	cargo	
and	fluid,	they	have	a	highly	dynamic	structure	with	a	high	propensity	to	undergo	homotypic	
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fusion.	Early	endosomes	mature	into	either	the	recycling	endosome	transferring	cargo	to	the	
plasma	membrane,	or	the	late	endosome	resulting	in	the	enrichment	of	tetraspanins	and	often	
a	large	accumulation	of	intraluminal	vesicles	(ILVs)	(25,	49,	54,	85).	The	formation	of	ILVs,	as	
well	as	the	protein	incorporation	into	ILVs,	is	driven	by	a	number	of	proteins	together	known	as	
the	endosomal	sorting	complexes	required	for	transport	(ESCRT).	Upon	acquiring	multiple	ILVs,	
the	late	endosome	can	also	be	referred	to	as	a	multivesicular	body	(MVB).	Often,	the	late	
endosome/MVB	fuses	with	the	lysosome	resulting	in	degradation;	however,	a	separate	fate	is	
fusion	with	the	plasma	membrane,	giving	way	to	extracellular	vesicle	release	as	the	late	
endosome/MVB	releases	it’s	ILVs	into	the	extracellular	milieu	(25,	49,	54,	85).		
Extracellular	vesicles	as	a	product	of	autophagic	unconventional	secretion	is	a	multistep	
process,	involving	a	number	of	distinct	and	dynamic	membrane	compartments.	The	exact	
mechanisms	and	pathways	responsible	for	autophagic	unconventional	secretion	are	unknown,	
yet	is	thought	to	play	a	role	in	the	secretion	of	cytosolic	cargo	of	which	lack	signals	of	export.	
Autophagic	secretion	begins	with	the	process	of	macroautophagy	whereby	elongation	of	a	
double	membrane,	or	phagophore,	is	initiated	via	the	ATG1/ULK1	complex	(66,	70,	75).	While	
sequestering	cytosolic	cargos,	the	phagophore	matures	into	the	double-membrane	vesicle	
known	as	the	autophagosome,	driven	by	the	lipidation	of	the	LC3	protein.	This	autophagosome	
continues	in	maturation,	accumulating	a	number	of	ILVs,	possibly	fusing	with	other	nearby	
MVBs	to	form	what	is	known	as	the	amphisome	(66,	70,	75).	This	amphisome	can	follow	one	of	
two	fates:	fusion	with	the	lysosome	in	which	enclosed	cargo	meets	degradative	enzymes	such	
as	glycosidases,	proteases	and	sulfatases,	or	fusion	with	the	plasma	membrane	resulting	in	the	
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release	of	the	amphisome’s	ILVs	as	extracellular	vesicles	(66,	70,	75,	82-84).	Interestingly,	the	
idea	that	the	two	pathways	are	underway	suggest	that	different	subpopulations	of	ILVs	exist	
simultaneously	within	cells,	one	population	destined	for	degradation,	the	other	released	as	
extracellular	vesicles.	
Tetraspanins	Give	Way	to	Extracellular	Vesicle	Biogenesis	
	 Tetraspanins	belong	to	a	conserved	transmembrane	family	of	glycoproteins	typically	
consisting	of	200-300	amino	acids	(28,	29,	45).	Often	tetraspanins	act	as	scaffolding	proteins,	
anchoring	multiple	proteins	to	one	area	of	the	plasma	membrane	in	what	as	known	as	a	cluster	
of	differentiation	(CD);	CDs	have	been	shown	to	be	a	successful	tool	for	in	the	
immunophenotyping	of	a	variety	of	cell	types,	as	well	as	extracellular	vesicles.	Kowal	et	al.,	
propose	the	differential	separation	of	extracellular	vesicles	via	immuno-isolation	using	CD9,	
CD63	and	CD81	in	hopes	of	allowing	a,	“proper	evaluation	of	the	molecular	mechanisms	of	
biogenesis	and	secretion	and	the	respective	functions	of	subtypes	of	extracellular	vesicles”	(28,	
p.	969).		
	 Ranging	from	25-65	kDa,	due	to	post-translational	glycosylation,	CD63	was	the	first	
characterized	tetraspanin	(45).	This	ubiquitously	expressed	protein	is	localized	within	the	
endosomal	system	and	the	cell	surface.	Most	often	associated	with	the	late	endosome/MVB	
and	lysosome,	CD63	consists	of	a	particular	consensus	motif	required	for	endocytosis	at	the	
plasma	membrane	and	has	also	been	implicated	in	direct	lysosomal	targeting	(45).	CD63	is	
approximately	seven	times	as	enriched	in	the	ILVs	of	the	MVB,	when	compare	to	the	
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endosomal	limiting	membrane.	Interestingly,	incorporation	of	CD63	into	the	ILVs	seems	to	be	
independent	of	the	ESCRT	machinery	(45).		
CD9	is	a	24	kDa	tetraspanin	and	is	reported	to	exhibit	both	promigratory	and	
antimigratory	properties	via	integrin-dependent	signaling	(29).	Associated	with	the	plasma	
membrane,	CD9	has	been	implicated	in	muscle	cell	fusion,	as	well	as	egg-sperm	fusion.	
Interestingly,	CD9	is	often	associated	or	in	complex	with	CD81,	a	26	kDa	cell	surface	
tetraspanin;	their	association	has	been	implicated	in	tumor	cell	behaviors	such	as	motility	via	
ligand	attachments	and	breast	cancer	cell	morphology	(29).	Alone,	CD81	plays	a	significant	role	
in	cell	attachment/entry	of	Hepatitis	C,	the	pathogenesis	of	the	Plasmodium	species,	as	well	as	
the	virion	assembly	and	release	of	HIV-1	(28,	29).		
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CHAPTER	TWO	
NOVEL	APPROACHES	TO	ANALYZING	SINGLE	EXTRACELLULAR	VESICLES	
Rather	than	assuming	homogeneity	within	the	extracellular	vesicle	population,	we	
hypothesize	that	distinct	populations	of	extracellular	vesicles	are	released,	and	that	
environmental	conditions	can	alter	this	population.	Previous	work	in	the	field	has	examined	
these	extracellular	vesicles	in	bulk,	examining	western	blots	of	cellular	protein	or	RNA	levels	
present	in	all	collected	extracellular	vesicles	via	RT-PCR,	from	a	given	cell	population.	To	
determine	the	heterogeneity	of	the	populations,	I	aim	to	evaluate	the	populations	of	secreted	
extracellular	vesicles	at	the	single	vesicle	level.	By	creating	new	methodologies	for	studying	
single	extracellular	vesicles,	this	allows	for	a	more	thorough	understanding	of	their	suspected	
involvement	in	a	variety	of	pathologies	such	as	HAND.		
In	order	to	concentrate	the	extracellular	vesicle	population	differential	centrifugation	
was	utilized	in	this	study,	although	there	are	various	methods	of	extracellular	vesicle	
purification	including	immunomagnetic	isolation	methods,	ultrafiltration	methods,	or	sucrose	
gradient	fractionation	methods.	Yet,	as	each	method	has	its	challenges	we	have	decided	to	
employ	the	the	“gold	standard”	of	purification	methods,	of	which	is	the	most	common	among	
vesicle	research	to	date	(92).		
Using	techniques	successful	in	studying	virions,	I	have	similarly	incorporated	fluorescent	
markers	into	secreted	extracellular	vesicles	by	fusing	a	fluorophore	such	as	GFP,	to	the	first	15	
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amino	acids	of	the	Src	protein	(S15);	this	provides	the	foundation	of	plasma	membrane	
incorporation	due	to	the	particular	positive	charge	and	propensity	to	undergo	a	myristoylation	
reaction.	The	first	15	amino	acids	of	the	Src	protein	undergo	a	myristoylation	reaction	at	the	
second	Glycine	reside	from	the	N-terminal,	acting	as	a	plasma	membrane	anchor.	Furthermore,	
with	its	high	number	of	arginines	and	lysines,	this	particular	stretch	of	basic	amino	acids	
increases	Src’s	propensity	for	the	plasma	membrane.	This	S15	membrane	marker	has	been	
shown	to	incorporate	throughout	the	plasma	membrane,	fluorescently	tag	budding	virions	
from	the	plasma	membrane	and	now	has	been	successful	in	providing	a	fluorescent	marker	of	
secreted	extracellular	vesicles.	Following	cellular	expression	of	the	S15	construct,	released	
extracellular	vesicles	can	be	analyzed	through	protein	co-localization	analysis	with	the	
utilization	of	the	canonical	vesicle	markers	CD9,	CD63	and	CD81,	as	well	as	lysosomal	marker	
LAMP1	and	TSG101.	Quantification	via	wide-field	deconvolution	microscopy	combined	with	
imaging	software,	allows	for	the	analysis	of	extracellular	vesicles	at	a	single	vesicle	level.		
Because	of	its	uniformity	and	sensitivity,	wide	field	deconvolution	microscopy	is	an	ideal	
tool	to	quantify	the	fluorescent	intensity	of	extracellular	vesicle	populations.	For	an	unbiased,	
high	throughput	analysis	algorithms	are	generated	utilizing	Bitplane	Imaris	imaging	software	to	
create	three	dimensional	surfaces	around	individual	extracellular	vesicles	(Figure	3).	For	
example,	surfaces	are	created	around	the	S15-GFP	membrane	marker	and	the	fluorescence	
intensity	of	other,	co-localized	markers	such	as	the	tetraspanin	CD63	or	LAMP1	within	these	
individual	S15	surfaces,	are	exported	as	individual	events	for	analysis.	In	this	way,	it	is	possible		
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Figure	3.	Representative	Sample	of	Surface	Masks.	The	left	panel	shows	an	
example	of	an	acquired	image	in	one	fluorescent	channel	of	interest.	Surface	
algorithms	are	generated	to	detect	puncta	within	various	parameters.	
 
to	analyze	and	compare	large	quantities	of	extracellular	vesicles	containing	the	S15-GFP	and	
Immunofluorescent	markers	to	determine	their	heterogeneous	nature.			
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CHAPTER	THREE	
OVERALL	HYPOTHESIS	AND	EXPERIMENTAL	GOALS	
The	pathways	of	extracellular	vesicle	communication	and	their	selective	cargoes	can	
become	hijacked	in	the	context	of	many	diseases,	including	viral	infection,	thus	contributing	to	
the	pathogenesis	of	HAND.	In	HIV-1	positive	patients	undergoing	CART,	viremia	is	potently	
suppressed,	preventing	the	development	of	AIDS.	However,	these	CART-suppressed	individuals	
still	exhibit	non-AIDS	disease	states	such	as	HAND,	which	include	neurological	disorders	with	
varying	severity.	Current	literature	suggests	that	extracellular	vesicles	may	be	involved	in	the	
pathogenesis	of	HAND	in	the	CNS	as	they	are	believed	to	be	transferring	HIV-1	proteins,	
including	Tat,	Nef	and	Vpr,	to	nearby	neuronal	cells.	Overall,	I	hypothesize	that	extracellular	
vesicles	containing	HIV-1	proteins	are	of	a	heterogeneous	population.	By	achieving	a	better	
understanding	of	the	molecular	and	cellular	mechanisms	which	lead	to	the	pathology	of	HAND	
in	HIV-1	patients,	therapeutic	interventions	can	become	a	possibility.	
To	begin	addressing	the	pathogenesis	of	HAND	in	the	CNS,	a	foundation	of	study	must	
be	established	and	primitive	questions	must	first	be	addressed.	Ultimately	analyzing	
extracellular	vesicles	derived	from	HIV-1	infected	cells	is	most	applicable	in	a	disease-state	
model,	yet	to	analyze	the	population	of	extracellular	vesicles	released	following	HIV-1	infection	
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would	require	a	reliable	method	of	separating	virus	from	extracellular	vesicles.	Physical	and	
chemical	characteristics,	as	well	as	biogenesis	pathways	are	almost	identical	between	
extracellular	vesicles	and	virions	causing	an	analysis	such	as	this	very	challenging.	In	a	
foundational	study	such	as	this	the	main	focus	is	to	validate	a	method	of	single	vesicle	analysis,	
as	well	as	just	begin	the	study	of	vesicle	populations	containing	HIV-1	proteins.		
	Through	the	achievement	of	two	experimental	goals,	I	hope	to	better	understand	
populations	of	extracellular	vesicles	containing	HIV-1	proteins	and	approach	the	answers	to	
some	of	the	following	questions.	Do	extracellular	vesicles	contain	HIV-1	proteins	Tat,	Nef	or	
Vpr?	Are	these	vesicles	similar	to	one	another?	Can	we	decipher	the	possible	biogenesis	of	
subsets	of	extracellular	vesicle	populations?	Will	the	canonical	biomarkers	CD9,	CD63	and	
CD81provide	useful	information	of	these	extracellular	vesicles?	Will	LAMP1	or	TSG101	allow	us	
to	draw	conclusions	of	their	biogenesis?		
Experimental	Goal:	Determine	if	distinct	populations	of	extracellular	vesicles	are	
released	within	and	among	cell	types.	Through	the	developed	method	previously	described	in	
Chapter	Two,	I	aim	to	analyze	extracellular	vesicle	populations	at	the	single	vesicle	level.	The	
common	vesicle	markers	CD9,	CD81	and	CD63,	as	well	as	LAMP1	and	TSG101,	will	be	utilized	to	
characterize	populations	based	on	their	co-localization	analyses.	Assessment	at	the	level	of	a	
single	vesicle	will	shed	light	on	their	heterogeneity	and	begin	unique	analysis	of	their	suspected	
involvement	in	a	variety	cellular	processes.		
Experimental	Goal:	Define	the	cell	surface	markers	of	extracellular	vesicles	containing	
HIV-1	proteins	relevant	to	HAND.	Following	the	validation	of	single	extracellular	vesicle	analysis,	
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I	aim	to	determine	if/how	HIV-1	viral	protein	expression,	specifically	Tat,	Nef	or	Vpr,	influences	
the	quantity	and	quality	of	extracellular	vesicle	populations.	Again,	the	common	vesicle	markers	
CD9,	CD81	and	CD63,	as	well	as	LAMP1	and	TSG101,	will	be	utilized	to	characterize	these	
populations	of	particular	interest.	Simultaneous	assessment	of	these	markers	on	thousands	of	
extracellular	vesicles	will	allow	a	previously	unachieved	appreciation	for	the	specific	vesicle	
populations	produced	before	and	after	HIV-1	viral	protein	expression.	
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CHAPTER	FOUR	
DISTINCT	POPULATIONS	OF	EXTRACELLULAR	VESICLES	ARE	RELEASED	WITHIN	AND	
AMONG	CELL	TYPES	
Materials	and	Methods	
Cell	Culture.		
HEK	293T	(293T)	cells	were	cultured	at	37	degrees	Celsius	and	5	percent	Carbon	Dioxide	
in	Dulbecco’s	modified	Eagle’s	Medium	(DMEM)	containing	phenol	red	(Invitrogen),	
supplemented	with	the	addition	of	10	percent	fetal	bovine	serum	(FBS)	(Hyclone),	100	IU/ml	
penicillin,	100	ug/ml	streptomycin	and	10	ug/ml	ciprofloxacin	hydrochloride.		
Mesenchymal	Stem	Cells	(MSCs)	were	cultured	at	37	degrees	Celsius	and	5	percent	
Carbon	Dioxide	in	Iscvoe’s	Modified	Dulbecco	Minimum	Essential	Medium	(IDMEM)	containing	
phenol	red	(Invitrogen),	supplemented	with	the	addition	of	10	percent	fetal	bovine	serum	(FBS)	
(Hyclone),	10	percent	horse	serum	(Hyclone),	100	IU/ml	penicillin,	100	ug/ml	streptomycin	and	
10	ug/ml	ciprofloxacin	hydrochloride.	
Transfection	of	S15	GFP	Construct	and	Extracellular	Vesicle	Collection.	
293T	cells	were	transfected	at	approximately	60	percent	confluency	using	
Polyethylenimine	(PEI),	with	equal	parts	of	psPax2	and	S15-GFP	plasmids.	Cell	supernatant	was	
collected	48,	72	and	96	hours	post-transfection	for	extracellular	vesicle	collection	via	
differential	ultracentrifugation.	For	the	vesicle	collection,	collected	supernatant	was	first	spun	
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at	4,000g	for	20	minutes,	10,000g	for	30	minutes	and	100,000g	for	70	minutes.	The	pelleted	
vesicles	were	then	re-suspended	in	PBS	and	spun	at	100,000g	for	70	minutes.	All	differential	
centrifugation	was	performed	in	4	degrees	Celsius.	Concentrated	extracellular	vesicle	pellets	
were	re-suspended	in	PBS	and	stored	at	-80	Celsius.	
Immunofluorescent	Staining.	
For	extracellular	vesicle	visualization	experiments,	collected	vesicles	were	spinoculated	
onto	glass	coverslips	at	13	degrees	Celsius	for	2	hours	at	1200g	and	subsequently	fixed	with	a	
solution	consisting	of	0.1	M	PIPES	and	3.7	percent	formaldehyde	(Polysciences)	for	5	minutes.	
Following	fixation,	vesicles	were	incubated	with	the	following	possible	primary	antibodies	at	a	
concentration	of	1:1000:	mouse	anti-CD9	(BD	Pharmigen),	mouse	anti-CD63	(BD	Pharmigen),	
mouse	anti-CD81	(BD	Pharmigen),	or	mouse	anti-TSG101	(Santa	Cruz	Biotechnology	Inc.)	along	
with	the	rabbit	anti-Lamp1	antibody	(Abcam),	in	a	PBS	block	solution	supplemented	with	10	
percent	normal	donkey	serum	(NDS),	and	0.01	percent	NaN3	for	1	hour.	Following	primary	
antibody	incubation	vesicles	were	incubated	with	their	respective	secondary	antibody	
conjugated	to	a	fluorophore,	either	donkey	anti-mouse	594-conjugated	or	donkey	anti-rabbit	
647-conjugated,	at	a	concentration	of	1:400,	for	20	minutes	in	the	same,	above	described	PBS	
block	solution.		
Wide-Field	Deconvolution	Microscopy	and	Analysis.	
Extracellular	vesicle	images	were	taken	on	a	DeltaVision	wide	field	fluorescent	
microscope	(Applied	Precision,	GE)	outfitted	with	a	digital	camera	(CoolSNAP	HQ;	
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Photometrics),	while	using	a	1.4	numerical	aperture,	and	60	X	objective	lens.	The	acquired	
images	were	deconvolved	with	the	SoftWoRx	deconvolution	software	(Applied	Precision)	and	
analyzed	on	Bitplane:	Imaris	software	version	7.6.4.		
Puncta	were	analyzed	for	vesicle-like	characteristics,	such	as	size	and	sphericity,	and	a	
surface	algorithm	was	built	around	the	S15-GFP	signal.	The	maximum	fluorescence	intensity	
found	within	these	puncta	was	then	analyzed	and	cross	analyzed	with	the	other	perspective	
channels.		Finally,	all	acquired	images	were	subjected	to	the	same	algorithm	via	the	Batch	
Coordinator	tool	(Bitplane)	to	each	respective	signal.	All	statistical	analyses	and	graphs	were	
created	using	GraphPad	Prism	version	5.00	or	6.00	(GraphPad	Software,	Inc.).	
Results	and	Conclusions	
	 To	validate	the	proposed	methodology	of	single	vesicle	analysis,	extracellular	vesicles	
derived	from	transfected	S15-GFP	293T	cells	were	analyzed	following	collection,	
immunofluorescent	staining,	and	wide-field	deconvolution	microscopy.	Results	following	the	
CD63/LAMP1	protein	co-localization	analysis	reveal	the	vesicle	population	as	heterogeneous;	
whereby,	only	4.2	percent	of	S15-GFP	positive	puncta	are	also	positive	for	CD63	and	LAMP1.	
Furthermore,	S15-GFP	293T	vesicles	are	more	likely	to	be	CD63	positive,	rather	than	LAMP1	
positive,	as	CD63	positive	puncta	account	for	41.5	percent,	as	opposed	to	the	1.0	percent	found	
to	be	positive	for	LAMP1.	Interestingly,	a	large	proportion	of	S15	positive	293T	extracellular	
vesicles,	53.3	percent,	are	negative	for	both	LAMP1	and	CD63.	
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Figure 4. 293T Extracellular Vesicle Analysis. Here, we are depicting the colocation of the S15-GFP surface 
marker with either LAMP1 and CD63, or LAMP1 and CD81. Dot plots are sectioned into quadrants with 
corresponding percentages. The upper right quadrant quantifies the triple positive puncta, whereas the lower left 
quadrant quantifies the S15-GFP positive puncta alone. Bar graphs represent the summation of each quadrant, 
accounting for 100 percent of the S15-GFP positive puncta.  
 
	 S15-GFP	293T	extracellular	vesicle	co-localization	analysis	with	surface	markers	CD81	
and	LAMP1	reveal	similar	results	in	that	a	small	percentage,	3.5	percent,	are	LAMP1	positive.	
This	population	of	extracellular	vesicles	are	more	likely	to	be	CD81	positive,	revealing	a	51.2	
percent	positive	expression	profile,	and	12.3	percent	positive	for	both	LAMP1	and	CD81.	
Similarly,	this	analysis	reveals	a	significant	proportion	of	S15-GFP	extracellular	vesicles	are	
negative	for	either	CD81	or	LAMP1,	33.0	percent.			
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Following	analysis	of	S15-293T	extracellular	vesicles	and	determining	that	the	
methodology	utilized	for	individual	vesicle	analysis	has	been	successful,	it	was	of	interest	to	
examine	another	cell	type	to	determine	if	the	vesicle	populations	are	distinct	from	one	another.	
Extracellular	vesicles	derived	from	GFP	MSCs	were	analyzed	for	their	protein	co-localization,	
with	the	same	canonical	markers	utilized	in	characterizing	S15-GFP	293T	extracellular	vesicles.		
Interestingly,	the	protein	profile	derived	from	GFP	MSC	extracellular	vesicles	was	very	
unique,	in	comparison	to	the	S15-GFP	293T	derived	vesicles.	Extracellular	vesicles	derived	from	
GFP	MSCs	had	a	high	propensity	for	LAMP1,	and	showed	much	lower	levels	of	the	tetraspanin	
protein	markers	CD63	and	CD81.	Again,	this	analysis	reveals	a	significant	proportion	of	GFP	MSC	
extracellular	vesicles	are	negative	for	either	CD81	or	LAMP1,	30.5	percent,	and	negative	for	
either	CD61	or	LAMP1,	51.2	percent.		
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MSC GFP EXTRACELLULAR VESICLES 
Figure	5.	MSC	Extracellular	Vesicle	Analysis.	Here	we	are	depicting	the	colocalization	of	the	MSC	GFP	surface	
marker	with	either	CD81	and	LAMP1,	or	CD63	and	LAMP1.	Dot	plots	and	bar	graphs	are	arranged	in	the	same	
manner	as	described	in	Figure	4.		
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Overall,	when	comparing	the	vesicle	populations	of	S15-GFP	293T	and	GFP	MSCs,	it	is	
apparent	that	293T	extracellular	vesicles	have	a	much	higher	overall	intensity	level	than	the	
MSCs	in	GFP	expression,	CD63	and	CD81	tetraspanin	expression.	Interestingly,	intensity	of	
LAMP1	differ	in	that	the	MSC	extracellular	vesicles	have	a	much	higher	expression	profile,	than	
their	293T	counterpart.	Figure	6	depicts	the	comparison	analysis	of	max	intensity	of	each	
individual	puncta,	analyzed	from	within	their	own	channel	surface	mask.	Worth	observing	is	the	
              MSC EV Analysis 
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puncta	count	from	each	channel	surface	mask;	not	always	are	the	most	intense	puncta	the	
most	populous.		
Although,	it	must	be	addressed	that	the	conjugate	antibody	of	tetraspanins	CD63	and	
CD81	are	from	mouse;	therefore,	these	data	must	be	taken	lightly	as	MSCs	are	derived	from	
mice.	Fortunately,	the	LAMP1	conjugate	antibody	is	against	rabbit	allowing	the	data	to	be	fully	
interpreted	as	presented.		
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Figure	6.	Cell	Type	EV	Max	Intensity	Comparison	
Here,	we	are	comparing	the	fluorophore	signal	intensity	of	all	puncta	from	each	
surface	mask	created.	The	red	numbers	represent	the	total	puncta	number.	
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Figure	7:	Extracellular	Vesicle	Protein	Co-Localization	Analysis.	This	data	shows	the	summation	of	both	
S15-GFP	293T	and	GFP	MSC	vesicle	co-localization	analyses	with	either	CD81,	LAMP1,	CD81	and	LAMP1	
(top),	or	CD63,	LAMP1,	or	CD63	and	LAMP1	(bottom).	Bar	graphs	represent	the	summation	of	each	
protein	co-localization	analysis,	with	corresponding	colors.		
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CHAPTER	FIVE	
CELL	SURFACE	MARKERS	OF	EXTRACELLULAR	VESICLES	CONTAINING	HIV-1	PROTEINS	RELEVANT	
TO	HAND	
Materials	and	Methods	
Cell	Culture.		
HEK	293T	(293T)	cells	were	cultured	at	37	degrees	Celsius	and	5	percent	Carbon	Dioxide	
in	Dulbecco’s	modified	Eagle’s	Medium	(DMEM)	containing	phenol	red	(Invitrogen),	
supplemented	with	the	addition	of	10	percent	fetal	bovine	serum	(FBS)	(Hyclone),	100	IU/ml	
penicillin,	100	ug/ml	streptomycin	and	10	ug/ml	ciprofloxacin	hydrochloride.		
THP-1	cells	were	cultured	at	37	degrees	Celsius	and	5	percent	Carbon	Dioxide	in	Roswell	
Park	Memorial	Institute	medium	(RPMI)	containing	phenol	red	(Invitrogen),	supplemented	with	
the	addition	of	10	percent	fetal	bovine	serum	(FBS)	(Hyclone),	100	IU/ml	penicillin,	100	ug/ml	
streptomycin	and	10	ug/ml	ciprofloxacin	hydrochloride.		
Protein-GFP	Fusion	Constructs.		
Expression	plasmids	encoding	HIV-1	proteins	Nef,	Tat	and	Vpr	were	generated	by	PCR–
based	strategy.	First,	HIV-1	viral	proteins	Tat	and	Nef	were	fused	to	the	N-terminus	of	GFP	in	a	
pEGFP-N1	backbone	(Figure	7B,	7C).	Following	this,	the	Tat-GFP	fused	protein	was	subcloned	
into	the	multiple	cloning	site	of	the	lentiviral	backbone	(pLVX)	by	PCR-based	strategy	(Figure	
7A).			
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Transfection	of	Protein-GFP	Constructs	and	Generation	of	Stable	TAT-GFP	Cell	Line.	
293T	cells	were	transfected	at	approximately	60	percent	confluency	using	
Polyethylenimine	(PEI),	with	either	the	NEF-GFP-N1,	TAT-GFP-N1	or	GFP-VPR	plasmid.	Cell	
supernatant	was	collected	48,	72	and	96	hours	post-transfection	for	extracellular	vesicle	
collection	via	differential	ultracentrifugation.		
Lentivirus	for	transduction	was	produced	by	transfection	of	293T	cells	with	equal	parts	
of	vesicular	stomatitis	virus	glycoprotein	(VSV-G),	packaging	construct	psPax2,	and	Tat-GFP-
pLVX.	Viruses	were	harvested	48	hours	post-transfection,	filtered	through	a	0.45-µm	filter	
(Millipore),	and	used	to	transduce	THP-1	cells.	Cells	were	selected	48	hours	post-transduction	in	
RPMI	containing	5	µg/ml	puromycin	(Sigma-Aldrich).		
Extracellular	Vesicle	Collection.	
Collected	supernatant	was	first	spun	at	4,000g	for	20	minutes,	10,000g	for	30	minutes	
and	100,000g	for	70	minutes.	The	pelleted	vesicles	were	then	re-suspended	in	PBS	and	spun	at	
100,000g	for	70	minutes.	All	differential	centrifugation	was	performed	in	4	degrees	Celsius.	
Concentrated	extracellular	vesicle	pellets	were	re-suspended	in	PBS	and	stored	at	-80	Celsius.		
Immunofluorescent	Staining.	
For	extracellular	vesicle	visualization	experiments,	collected	vesicles	were	spinoculated	
onto	glass	coverslips	at	13	degrees	Celsius	for	2	hours	at	1200g	and	subsequently	fixed	with	a	
solution	consisting	of	0.1	M	PIPES	and	3.7	percent	formaldehyde	(Polysciences)	for	5	minutes.	
Following	fixation,	vesicles	were	incubated	with	the	following	possible	primary	antibodies	at	a	
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concentration	of	1:1000:	mouse	anti-CD9	(BD	Pharmigen),	mouse	anti-CD63	(BD	Pharmigen),	
mouse	anti-CD81	(BD	Pharmigen),	or	mouse	anti-TSG101	(Santa	Cruz	Biotechnology	Inc.)	along	
with	the	rabbit	anti-Lamp1	antibody	(Abcam),	in	a	PBS	block	solution	supplemented	with	10	
percent	normal	donkey	serum	(NDS),	and	0.01	percent	NaN3	for	1	hour.	Following	primary	
antibody	incubation	vesicles	were	incubated	with	their	respective	secondary	antibody	
conjugated	to	a	fluorophore,	either	donkey	anti-mouse	594-conjugated	or	donkey	anti-rabbit	
647-conjugated,	at	a	concentration	of	1:400,	for	20	minutes	in	the	same,	above	described	PBS	
block	solution.		
Wide-Field	Deconvolution	Microscopy	and	Analysis.	
Extracellular	vesicle	images	were	taken	on	a	DeltaVision	wide	field	fluorescent	
microscope	(Applied	Precision,	GE)	outfitted	with	a	digital	camera	(CoolSNAP	HQ;	
Photometrics),	while	using	a	1.4	numerical	aperture,	and	60	X	objective	lens.	The	acquired	
images	were	deconvolved	with	the	SoftWoRx	deconvolution	software	(Applied	Precision)	and	
analyzed	on	Bitplane:	Imaris	software	version	7.6.4.			
Puncta	were	analyzed	for	vesicle-like	characteristics,	such	as	size	and	sphericity,	and	a	
surface	algorithm	was	built	around	the	GFP	signal.	The	maximum	fluorescence	intensity	found	
within	these	puncta	was	then	analyzed	and	cross	analyzed	with	the	other	perspective	channels.	
Finally,	all	acquired	images	were	subjected	to	the	same	algorithm	via	the	Batch	
Coordinator	tool	(Bitplane)	to	each	respective	signal.	All	statistical	analyses	and	graphs	were	
created	using	GraphPad	Prism	version	5.00	or	6.00	(GraphPad	Software,	Inc.).	
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Results	and	Conclusions	
Extracellular	vesicles	may	be	the	result	of	secretion	directly	from	the	plasma	membrane,	
released	following	the	endocytic	pathway,	or	can	be	the	product	of	autophagic	unconventional	
secretion	(19,	20,	56-58).	Nef	extracellular	vesicles	are	less	than	5	percent	LAMP1	positive	
leading	us	to	believe	that	Nef	may	be	secreted	directly	from	the	plasma	membrane,	as	LAMP1	
is	associated	with	autophagic	unconventional	secretion.		These	data	correlate	well	with	the	
structural	model	of	Nef,	as	this	protein	consists	of	an	N-terminal	myristoylation,	causing	Nef	to	
be	a	membrane-associated	protein	(Figure	9C).	Furthermore,	the	previously	described	S15-GFP	
membrane	marker,	consisting	of	a	myristoylated	glycine	residue	and	positive	charges,	reveal	a	
similar	co-localization	analysis	with	LAMP1	at	approximately	5	percent.	Lastly,	the	extracellular	
vesicles	of	Nef	colocalize	more	so	with	the	tetraspanins	CD63	and	CD81,	of	which	are	known	to	
be	located	in	the	plasma	membrane	of	cells,	rather	than	the	late	endosome/MVB	tetraspanin	
CD9.	
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Figure	9.	Representative	Example	of	Triple	Co-Localization.	Panel	A	is	a	portion	of	the	total	image	achieved	of	
which	three	distinct	channels	are	visible.	Panel	B	reveals	a	number	of	surfaces	which	have	been	created	to	
detect	puncta	within	the	parameters	of	the	set	algorithm.	Triple	colocalization	can	be	detected	in	panel	C,	from	
each	individual	fluorescent	channel:	NEF-GFP	(D),	CD9	(E)	and	LAMP1(F).	
 
Figure	8.	Agarose	Gel	Electrophoresis	of	Generated	HIV-1	Protein	Plasmids.	
Panel	A	depicts	the	Tat-GFP-pLVX	clone.	Panel	B	depicts	the	Tat-pEGFP-N1	
clone.	Panel	C	depicts	the	Nef-pEGFP-N1	clone.		
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Figure	10.	293T	Nef-GFP	Extracellular	Vesicle	Protein	Co-Localization	Analyses	and	Protein	Structure.	(A)	This	
data	shows	the	summation	of	each	Nef-GFP	antibody	stain;	each	protein	co-localization	analysis	has	3	total	
data	replicates.	Error	bars	show	the	standard	error	of	the	mean.	(B)	Bar	graphs	to	represent	the	summation	of	
each	protein	co-localization	analysis.	(C)	Structural	example	of	HIV-1	protein	Nef.	
 
	
	
	
	
	
	
	
	
	
	
	
	
Unlike	Nef	extracellular	vesicles,	Tat	profiles	are	nearing	20	percent	positive	for	LAMP1,	
suggesting	their	release	is	more	associated	with	the	autophagic	unconventional	secretion	
pathway.	Yet,	as	the	data	present	Tat	often	colocalizes	with	CD63	and	CD81	as	well	suggesting	
their	release	directly	from	the	plasma	membrane.	Although	confounding,	these	Tat	single	
vesicle	analyses	may	lead	to	the	conclusion	that	this	particular	HIV-1	protein	is	packaged	and	
released	within	vesicles	from	multiple,	or	more	than	one	pathway.		
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Similar	to	extracellular	vesicles	released	from	Tat-GFP	293T	cells,	Tat-GFP	THP-1	
extracellular	vesicles	are	nearing	20	percent	positive	for	LAMP1,	yet	expression	of	tetraspanins	
CD9,	CD63,	CD81	and	ESCRT	protein	TSG101	have	all	decreased.	Possibly	THP-1	Tat	vesicles	are	
associated	with	the	autophagic	unconventional	secretion	pathway.		
	
	
	
	
	
Figure	11.	293T	Tat-GFP	Extracellular	Vesicle	Protein	Co-Localization.	This	data	shows	the	summation	of	each	
Tat-GFP	antibody	stain;	each	protein	co-localization	analysis	has	3	total	data	replicates.	Error	bars	show	the	
standard	error	of	the	mean.	Bar	graphs	to	represent	the	summation	of	each	protein	co-localization	analysis.		
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Figure	12.	THP-1	Tat-GFP	Extracellular	Vesicle	Protein	Co-Localization.	This	data	shows	the	summation	of	
each	Tat-GFP	antibody	stain;	each	protein	co-localization	analysis	has	3	total	data	replicates.	Error	bars	show	
the	standard	error	of	the	mean.	Bar	graphs	to	represent	the	summation	of	each	protein	co-localization	
analysis.		
 
	
	
	
	
	
	
	
	
	
	
	
	
	
Extracellular	vesicles	released	from	GFP-Vpr	expressing	293T	cells	present	with	a	protein	
co-localization	profile	more	similar	to	293T	Tat-GFP	vesicles,	than	293T	Nef-GFP	vesicles.	As	the	
data	present,	Vpr	vesicles	are	nearing	25	percent	positive	for	LAMP1,	suggesting	their	release	
are	more	associated	with	the	autophagic	unconventional	secretion	pathway.	Of	the	three	HIV-1	
protein	expressing	extracellular	vesicle	populations,	Vpr	vesicles	have	the	lowest	co-localization	
with	the	tetraspanins	CD9,	CD63	and	CD81,	yet	the	highest	expression	of	ESCRT	protein	
TSG101,	suggesting	that	Vpr	vesicles	may	be	derived	from	an	unconventional	secretion	
pathway	as	TSG101	is	a	protein	found	within	late	endosomes/MVB.				
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Figure	13.	293T	GFP-Vpr	Extracellular	Vesicle	Protein	Co-Localization.	This	data	shows	the	summation	of	each	
GFP-Vpr	antibody	stain;	each	protein	co-localization	analysis	has	3	total	data	replicates.	Error	bars	show	the	
standard	error	of	the	mean.	Bar	graphs	to	represent	the	summation	of	each	protein	co-localization	analysis.		
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CHAPTER	SIX	
DISCUSSION	
Extracellular	vesicle	analysis	at	the	level	of	individual	vesicles	provides	a	newfound	
appreciation	of	their	heterogeneous	population,	allowing	for	further	analysis	of	possible	
subpopulations.	Prior	to	this	work	the	techniques	most	often	utilized	to	study	extracellular	
vesicles	were	based	on	the	entire	population,	via	western	blot	or	RT-PCR,	constraining	
viewpoints	of	homogeneity.	The	validated	methodology	provided	in	this	study	has	the	potential	
to	be	utilized	in	the	examination	of	various	extracellular	vesicles	released	from	any	set	of	cells,	
under	a	variety	of	treatment	options,	allowing	a	broader	understanding	of	extracellular	vesicles.	
Moreover,	through	the	use	of	various	protein	markers	such	as	tetraspanins	CD9,	CD63	and	
CD81,	as	well	as	ESCRT	protein	TSG101	and	lysosomal	marker	LAMP1,	it	may	be	possible	to	
determine	the	biogenesis	of	extracellular	vesicles	implicated	in	HAND	pathogenesis.	
Immunofluorescent	staining	and	wide-field	deconvolution	microscopy	coupled	with	canonical	
vesicle	markers	allows	for	the	analysis	of	subpopulations	of	extracellular	vesicles	released	into	
the	extracellular	milieu.		
Results	from	this	study	revealed	that	distinct	vesicles	are	released	within	and	among	cell	
types.	The	S15-GFP	membrane-associated	marker	was	the	way	in	which	extracellular	vesicles	
were	visualized	for	further	analysis.	It	was	found	that	S15-GFP	293T	vesicles	were	less	than	5	
percent	LAMP1	positive	and	were	significantly	more	positive	for	tetraspanins	CD63	or	CD81
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suggesting	their	release	to	be	generated	directly	from	the	plasma	membrane	or	the	classic,	
exocytic	pathway	of	extracellular	biogenesis	rather	than	an	unconventional	autophagic	
secretion.	This	data	correlates	well	with	the	membrane-association	of	the	S15-GFP	marker,	yet	
through	our	analyses	it	became	apparent	that	not	all	extracellular	vesicles	were	S15-GFP	
positive	(especially	those	that	were	LAMP1	positive)	leading	us	to	believe	that	it	would	be	
beneficial	to	study	extracellular	vesicle	populations	with	a	more	inclusive	marker.	Possibly	
membrane-intercalating	fluorescent	dyes	would	be	a	more	appropriate	tool	in	the	analysis	of	
entire	extracellular	populations.	
This	methodology	of	single	vesicle	analysis	was	then	applied	to	a	second	cell	type,	MSCs	
as	they	were	readily	available.	GFP	MSC	extracellular	vesicles	had	a	unique	protein	co-
localization	profile,	being	much	more	LAMP1	positive	compared	to	the	S15-GFP	extracellular	
vesicles	released	from	293T	cells.	Interestingly,	MSCs	have	been	shown	to	have	extremely	high	
autophagosome	concentration	even	during	basal	state	which	correlates	with	the	data	
presented	here	(19).	Their	profile	of	tetraspanins	CD63	and	CD81,	are	insignificant	among	the	
vesicle	population,	yet	as	stated	previously	this	may	be	due,	in	part,	to	the	fact	that	the	primary	
antibody	for	these	tetraspanins	were	against	mouse	of	which	MSCs	are	derived.	It	would	be	of	
interest	to	analyze	MSC	extracellular	vesicles	with	the	appropriate	species	type	antibodies	to	
determine	their	true	tetraspanin	profile.		
	The	extracellular	vesicle	analyses	containing	HIV-1	proteins	relevant	to	HAND	display	
the	possibility	of	utilizing	this	technique	of	extracellular	vesicle	analysis	within	vesicle	
populations	implicated	in	pathogenesis.		HIV-1	proteins	Tat,	Nef	and	Vpr	were	of	interest	due	to	
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their	broad	association	in	HAND,	as	well	as	their	incorporation	into	extracellular	vesicle	
populations.	The	majority	of	these	studies	were	carried	out	with	the	utilization	of	293T	cells,	
allowing	for	the	foundation	of	single	vesicle	analysis	with	the	incorporation	of	HIV-1	proteins.	
As	might	be	expected	it	would	be	of	great	interest	to	continue	such	analyses	in	more	relevant	
cell	types,	such	as	THP-1	cells	differentiated	into	macrophages;	these	cells	would	bring	us	one	
step	closer	to	the	CNS	resident	microglia.		
Extracellular	vesicles	derived	from	cells	over-expressing	GFP	fusions	to	each	of	these	
proteins	of	interest,	present	with	unique	protein	co-localization	analyses.	The	population	of	
Nef-GFP	extracellular	vesicles	was	found	to	be	highly	associated	with	tetraspanins	CD63	and	
CD81	and	less	so	with	CD9,	TSG101	and	LAMP1.	These	data	fall	in	line	with	the	structure	of	Nef,	
as	myristoylation	allows	for	plasma	membrane	association,	much	like	the	S15-GFP	membrane	
marker.	It	would	be	of	great	interest	to	determine	if	other,	more	HIV-1	applicable	cell	lines	such	
as	THP-1	cells,	have	similar	extracellular	vesicle	characterizations.	Unfortunately	for	this	study	
time	did	not	permit	those	analyses.	
	In	comparison,	Tat-GFP	vesicles,	both	derived	from	293T	and	THP-1	cells,	are	more	
inclined	to	be	positive	for	all	markers	including	tetraspanins	CD9,	CD63	and	CD81,	TSG101,	and	
LAMP1.	Quite	possibly	Tat	protein	is	released	within	multiple	vesicle	populations,	derived	from	
various	biogenesis	pathways,	as	literature	suggests	states	of	disease	and	alterations	of	cellular	
metabolism	perturb	the	cells	natural	extracellular	vesicle	biogenesis	pathways	(6,	15,	18,	21).	
Tat,	a	protein	known	to	be	often	secreted	from	HIV-1	infected	cells,	may	incorporate	itself	into	
many	extracellular	populations	for	means	of	exiting	the	cell.	
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Lastly,	GFP-Vpr	extracellular	vesicles	present	with	the	highest	expression	of	ESCRT	
protein	TSG101;	this	suggests	that	their	release	may	be	more	connected	to	the	classic,	exocytic	
pathway	of	extracellular	biogenesis	as	TSG101,	an	ESCRT	protein,	is	often	found	within	late	
endosomes/MVB.	With	hopes	of	studying	this	viral	protein	in	a	more	relevant	HIV-1	disease	
model	cell	line,	THP-1	cells	were	generated	to	express	GFP-Vpr	via	transduction.	Unfortunately,	
these	cells	were	unable	to	thrive	as	the	Vpr	protein	is	known	to	cause	G2	cycle	arrest.	A	
doxycycline-inducible	system	was	of	interest,	as	it	would	potentially	allow	for	limited	
expression	of	Vpr,	yet	despite	many	attempts	it	was	regrettably	unsuccessful	during	this	study.	
After	analyzing	obtained	data	it	became	apparent	that	although	various	markers	were	
utilized	with	the	goal	of	characterizing	the	whole	extracellular	vesicle	populations,	a	large	
proportion	of	vesicles	were	negative	for	any	of	the	chosen	markers.	This	limitation	is	possibly	
the	result	of	surface	algorithms	created	to	detect	positive	puncta.	Such	algorithms	created	for	
each	channel	of	interest	have	been	applied	to	thousands	of	extracellular	vesicles	with	
background	levels	derived	from	the	secondary	antibody	only	controls.	Quite	possibly	during	the	
analysis,	the	detection	methods	utilized	were	too	conservative	excluding	positive	puncta.	
Alternatively,	is	would	be	of	interest	to	include	a	broader	range	of	both	integral,	as	well	as	
transmembrane	proteins	for	further	characterization	of	the	extracellular	vesicle	population.	
Perhaps,	the	inclusion	of	heat	shock	proteins	or	membrane	transport	proteins	may	better	
reveal	the	true	characteristics	of	all	extracellular	vesicles	obtained.		
In	future	studies	involving	extracellular	vesicles	containing	HIV-1	proteins,	it	would	be	
revealing	to	expose	neuronal	cell	lines	to	each	extracellular	vesicle	population	individually	(Nef,	
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Tat,	or	Vpr)	to	determine	their	deleterious	effects.	Quite	possibly	one	protein	is	more	
neurotoxic	than	the	next	or	even	one	pathway	of	extracellular	vesicle	biogenesis	produces	
more	neurotoxic	vesicles.	To	begin	to	address	the	latter,	future	studies	may	utilize	various	
pharmacological	treatments	to	inhibit	one	or	more	extracellular	vesicle	biogenesis	pathways.	
For	instance,	Bafilomycin	A1	may	be	utilized	to	inhibit	the	production	of	lysosomes	or	MG132	
to	perturb	the	formation	of	autophagosome,	thus	altering	pathways	of	cellular	degradation	and	
vesicle	biogenesis.				
Additionally,	it	would	be	meaningful	to	determine	how	prevalent	Nef,	Tat	or	Vpr	are	
among	the	entire	vesicle	population	released	from	HIV-1	infected	cells.	Possibly	as	a	result	of	
HIV-1	infection,	the	extracellular	vesicle	populations	are	altered	even	more	so	than	during	the	
single	protein	expression	induced	here.	To	analyze	the	population	of	extracellular	vesicles	
released	following	HIV-1	infection	would	require	a	reliable	method	of	separating	virus	from	
extracellular	vesicles.	Physical	and	chemical	characteristics,	as	well	as	biogenesis	pathways	are	
almost	identical	between	extracellular	vesicles	and	virions	causing	an	analysis	such	as	this	very	
challenging.		
In	this	thesis	of,	THE	NOVEL	CHARACTERIZATION	OF	EXTRACELLULAR	VESICLES	
CONTAINING	PROTEINS	WHICH	HAVE	BEEN	IMPLICATED	IN	THE	PATHOGENESIS	OF	HIV	
ASSOICIATED	NEUROCOGNITIVE	DISORDERS	we	have	shown	that	extracellular	vesicles	
containing	HIV-1	proteins	are	not	of	a	homogeneous	population.	Through	the	utilization	of	
canonical	markers	and	wide-field	deconvolution	microscopy	we	can	analyze	the	larger	
population	at	the	single	vesicle	level	to	determine	their	possible	mode	of	biogenesis.		This	study	
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provides	the	foundation	in	characterizing	and	better	understanding	extracellular	vesicles	which	
may	be	responsible	for	the	pathogenesis	of	a	multitude	of	neuropathological	disorders.
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